5 completed, 1 withdrawn. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Unresectable Extrahepatic Bile Duct Carcinoma: new trials by email Literature Review of Unresectable Extrahepatic Bile Duct Carcinoma trials Research Report on Unresectable Extrahepatic Bile Duct Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
| Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma | Phase 1 | Withdrawn | Mayo Clinic | 2017-05-01 | 2017-05-30 | |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2015-04-02 | 2022-02-02 |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Capecitabine, Fluorouracil, Laboratory Biomarker Analysis - Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2014-02-01 | 2017-09-12 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-04-01 | 2016-06-17 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2010-04-01 | 2015-06-30 |
Gallbladder Neoplasms (5) · Cholangiocarcinoma (4) · Bile Duct Neoplasms (3) · Klatskin Tumor (3) · Carcinoma, Hepatocellular (2)
Adenocarcinoma (6) · Biliary Tract Diseases (6) · Biliary Tract Neoplasms (6) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Gallbladder Diseases (5) · Bile Duct Diseases (3) · Liver Diseases (2) · Liver Neoplasms (2) · Cholangiocarcinoma (1)
1,2-diaminocyclohexaneplatinum II citrate (3) · Cisplatin (3) · Gemcitabine (3) · Platinum (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Taxes (2) · Capecitabine (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1) · Leucovorin (1) · MK 2206 (1) · Sorafenib (1) · dehydroftorafur (1) · ricolinostat (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1)
United States (6)
Anthony El-Khoueiry (1) · Kabir Mody (1) · Milind Javle (1) · Rachna Shroff (1) · Richard Kim (1) · Tanios Bekaii-Saab (1)
U10CA032102 (2), U10CA180888 (2), N01CM00070 (1), P30CA015083 (1), P30CA016058 (1)